

Assessing the potential impacts on U.S. health care in an election year



From the Field
June 2024

Key Insights

- While health care historically has been one of the hottest political potatoes in the lead-up to a U.S. presidential election, discussions this campaign have been more subdued.
- Perhaps the biggest issue at stake is in relation to the future of the Affordable Care Act, aka Obamacare, with potentially binary impacts depending on the election outcome.
- Both leading candidates have voiced concerns about rampant health care cost inflation, and each appears committed to reducing the high cost of prescription drugs.




Jill Jortner
*Health Care Sector
Investment Analyst,
T. Rowe Price*

The 2024 U.S. presidential election campaign has been noteworthy for the lack of big-ticket issues or policies from either leading candidate. Health care, for example, historically has been one of the hottest of all political potatoes during election years, given the scope for impactful change, but it has featured much less prominently in either candidate's campaigning in this election cycle. This low-key focus has been less disruptive for the health care sector than in recent election year campaigns, a fact duly reflected on the markets, with the sector posting positive returns in 2024 to date, albeit trailing the broader equity market's rally.

“ Health care, for example, historically has been one of the hottest of all political potatoes during election years....

Health care returns have been inconsistent in election years

(Fig. 1) Annual relative returns in U.S. election years (S&P health care sector vs. S&P 500)



As of May 15, 2024. Annual total returns.

Past performance is not a reliable indicator of future performance.

Index performance is for illustrative purposes only and is not indicative of any specific investment.

Investors cannot invest directly in an index.

¹ Year to date as of May 15, 2024.

Source: Refinitiv Eikon. © 2024 Refinitiv. All rights reserved. Analysis by T. Rowe Price.

By way of comparison, recent election years show the health care sector performing inconsistently, delivering an array of negative and positive annual returns in different election years (Fig. 1). This erratic track record has much to do with how central a topic health care has been in each election campaign and how significant the proposed changes to the U.S. health care system have been in the lead-up to each election. One only needs to look back to the 2019–2020 campaign trail, when Democrat candidates proposed wholesale change in the form of “Medicare for All,” a single-payer health system, to understand the pivotal role that health care can play in an election campaign.

With health care not being central to either candidate’s campaign talking points in 2024, the biggest impact on the sector is likely to come from which candidate ultimately wins and what this might mean for key health care issues. In this paper, we delve deeper into some of these contentious health care areas and consider the potential impacts depending upon who is elected come November.

“ One of the most divisive—and decisive—
areas of U.S. health care is the managed
care industry...

U.S. managed care could see binary impacts

One of the most divisive—and decisive—areas of U.S. health care is the managed care industry, where ideology sees each candidate diametrically opposed in their view of, and approach to, providing health care to the American population.

Drilling down into the broad managed care landscape, we see four key topics that are likely to be central areas of focus for both candidates but that could see very different impacts, depending on who is ultimately elected the next U.S. president. We consider each of these below, from both sides of the political aisle.



If Joe Biden is elected:

1. The Affordable Care Act

During his current term of office, President Biden has gone to great lengths to strengthen the Affordable Care Act (ACA)—also known as Obamacare—and expand affordable health care coverage to more Americans. Since his election, President Biden meaningfully strengthened the ACA exchanges, which allow individuals to shop for subsidized health insurance plans, both through the introduction of enhanced subsidies in 2021, and increasing the income levels eligible for subsidy. An increase in marketing spending also aided ACA exchange awareness. During the most recent 2024 enrollment period, some 21 million Americans signed up for health insurance coverage through ACA exchanges—the highest-ever total—and a massive increase from 11.4 million members in 2020.¹

With the expanded subsidies set to sunset in 2025, President Biden will be keen to try and make these subsidies permanent should he secure a second term. The main beneficiaries of an extension of the subsidies and continued growth in the ACA exchange enrollment will be managed care companies with sizable exchange businesses, along with providers who have seen incremental volume growth and improved payer mix associated with the increasing exchange membership.

2. Medicare

Under a reelected Biden administration, Medicare—the government-funded health plan primarily for older Americans—is likely to see a continuation of the status quo. While not expected at the time of the 2020 election, President Biden and the Democratic administrators at Centers for Medicare and Medicaid, which sets Medicare policy and rates, has put forth policies that have been much more onerous than expected for the Medicare Advantage (MA) industry.

Many of the adjustments made to the Medicare program thus far have created new headwinds to profitability for Medicare plans. These have included meaningful changes to the “risk model,” which MA plans use to determine individual beneficiary payment rates, and much more modest Medicare Advantage rate updates than the industry received during the Trump administration. While a reelection of President Biden should be a continuation of the status quo, the last two rate-setting cycles have created challenges for the MA industry, and as such, we believe the industry would welcome a change in administration.

3. Hospitals and health services

U.S. hospitals have been meaningful beneficiaries of the expanded ACA subsidies introduced under the Biden administration, driving increased patient volumes coming from newly insured ACA enrollees. Since commercial insurance typically reimburses hospitals at higher rates than government programs such as Medicare and Medicaid, and most certainly relative to uninsured patients, the growth in ACA-insured patients in hospitals has also contributed to higher profit margins for hospitals. A likely continuation of the ACA subsidies under a reelected Biden administration would see this trend continue.

Less positively, since taking office, the current administration has also attempted to control consolidation in the hospital subsector, including banning several planned mergers. While hospital mergers are ideally supposed to create cost efficiencies among often struggling hospitals, the creation of huge conglomerates and hospital networks has driven up U.S. medical costs, with some boasting near-monopoly pricing power.

4. Drug pricing

The main uncertainty in relation to drug pricing revolves around legislation introduced under the Inflation Reduction Act (IRA) giving Medicare (under Part D of the program, which covers drug prescriptions and subsidies available to plan members) the power for the first time to negotiate drug prices with manufacturers. The negotiations began in August 2023, with 10 drugs selected, and older Americans are already seeing lower out-of-pocket costs.

By the time the redesign of Part D is fully implemented in late 2025, it is expected that pharmaceutical companies will be picking up a considerably larger portion of U.S. prescription drug costs than has previously been the case. If reelected, President Biden would continue to push through measures introduced under the IRA, potentially expanding the number of drugs eligible for price negotiation. In December 2023, the Biden administration also announced new plans to boost competition in the pharmaceutical sector, while ensuring lower prescription drug costs.

¹ KFF—independent provider of U.S. health policy polling and research. As of January 24, 2024.



If Donald Trump is elected:

1. The Affordable Care Act

Former President Trump has resumed his criticism of the ACA this campaign, and vowed to repeal and replace the legislation if he is reelected. While a full repeal and replace is highly unlikely, having failed during President Trump's prior term, if reelected, President Trump could embark on efforts to weaken key provisions of the ACA.

One key element of the ACA that a Trump victory could impact would be the expanded ACA subsidies that are set to expire at the end of 2025 and would require legislative action to be extended. Other levers available to President Trump, if elected, would be to scale back on ACA marketing investments and, on the Medicaid side, increasing the power of states to restrict eligibility to Medicaid via work requirements and other measures.

2. Medicare

A reelection of former President Trump would likely be more positive for the MA program, as his actions in his first presidential term served to strengthen funding for MA and increase the penetration relative to traditional fee-for-service Medicare. While a Trump reelection would be a "net win" for the Medicare plans, it is not known if President Trump would be as supportive of MA in a second term as he was in his first due to increasing rhetoric in Washington on both sides of the political aisle around overpayments to Medicare Advantage plans relative to fee for service.

3. Hospitals and health services

There is concern among investors in hospitals that a Trump administration is unlikely to extend the expanded ACA subsidies once they expire in 2025. These subsidies have driven a sharp increase in ACA enrollment, which has led to an increase in hospital admissions and provided a boost to hospital profitability in recent years.

That said, there is one significant consideration that may give former President Trump reason for pause, namely the fact that the constituents in the key Republican states of Texas and Florida have been huge beneficiaries of the expanded ACA subsidies with ACA enrollment up 120% in Florida and 210% in Texas since 2020. The Trump administration would have to consider both the impact on constituents (voters) in these states, with 4.6 million individuals gaining coverage since 2020 in these two states, as well as the locally important hospital industry. The publicly traded for-profit hospital companies are highly exposed to Texas and Florida, where the most growth in ACA exchange enrollment has been seen.

State hospitals, which are also large employers in their local markets; state governments; and, importantly, local voters, have all benefited to varying degrees. So, cutting off the current expanded ACA subsidies completely in 2025 may be easier said than done.

4. Drug pricing

Drug pricing has not featured as prominently as it has in previous election campaigns; however, the high cost of prescription medicine remains an important issue on both sides of the political spectrum. Both candidates have voiced a desire to rein in health care inflation and reduce drug prices, albeit via different means. During his time in office, President Trump floated the idea of implementing a "Favored Nation Model," whereby Medicare Part B prescription drug prices would be pegged to the lowest price paid by other developed nations. While the proposal was ultimately blocked, it highlights a clear commitment to act on what is a key issue for American voters.

Whether or not a new Trump administration would continue with the price negotiation powers granted to Medicare under the IRA remains to be seen. To date, President Trump has said little on this, nor has he proposed any alternative policies aimed at reducing drug prices. Suffice it to say that, previously, President Trump has not been a particular friend to "big pharma," so a return to office is unlikely to be more favorable than a Biden administration for the sector, and possibly much less so.

Health care spending will continue to rise, but beneficiaries will differ

Whoever ultimately is elected the next U.S. president in November, we would expect health care spending to continue rising under either a Biden or a Trump administration. Even though both candidates have voiced a desire to bring down medical inflation, and specifically to rein in high drug prices, total spending will continue to be driven higher by patient demand, an aging population, and the cost of medical services and innovation. Our expectation, should President Biden win, is for total health care expenditure to increase, with public spending outpacing private. An early budgetary port of call for a new Biden administration is likely to be an extension to the expanded ACA subsidies. In contrast, if President Trump is reelected, we anticipate that he will move to reduce or eliminate the expanded federal subsidies, as well as reduce funding for several health programs, including Medicaid. While any attempts to overturn Obamacare fully are unlikely to succeed, weakening the ACA could ultimately see higher costs and reduced coverage for lower-income Americans. In the event of a Trump victory, we would anticipate increased private health expenditure, at the expense of public programs, while pharmaceutical companies could also be better off, should a new Trump administration revoke Medicare's power to negotiate drug prices directly.

T. Rowe Price cautions that economic estimates and forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Actual outcomes could differ materially from those anticipated in estimates and forward-looking statements, and future results could differ materially from historical performance. The information presented herein is shown for illustrative, informational purposes only. Any historical data used as a basis for analysis are based on information gathered by T. Rowe Price and from third-party sources and have not been verified. Forecasts are based on subjective estimates about market environments that may never occur. Any forward-looking statements speak only as of the date they are made. T. Rowe Price assumes no duty to, and does not undertake to, update forward-looking statements.

INVEST WITH CONFIDENCE™

T. Rowe Price identifies and actively invests in opportunities to help people thrive in an evolving world, bringing our dynamic perspective and meaningful partnership to clients so they can feel more confident.

Important Information

This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

DISCLOSURE CONTINUES ON THE FOLLOWING PAGE.

Important Information (cont.)

Australia—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. For Wholesale Clients only.

Brunei—This material can only be delivered to certain specific institutional investors for informational purpose only. Any strategy and/or any products associated with the strategy discussed herein has not been authorised for distribution in Brunei. No distribution of this material to any member of the public in Brunei is permitted.

Canada—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.'s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

Colombia, Chile, Mexico, Peru, Uruguay—This material is prepared by T. Rowe Price International Ltd - Warwick Court, 5 Paternoster Square, London, EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority - and issued and distributed by locally authorized distributors only. For professional investors only.

DIFC—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd which is regulated by the Dubai Financial Services Authority as a Representative Office. For Professional Clients only.

EEA—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

Hong Kong—Issued in Hong Kong by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.

Indonesia—This material is intended to be used only by the designated recipient to whom T. Rowe Price delivered; it is for institutional use only. Under no circumstances should the material, in whole or in part, be copied, redistributed or shared, in any medium, without prior written consent from T. Rowe Price. No distribution of this material to members of the public in any jurisdiction is permitted.

Korea—This material is intended only to Qualified Professional Investors. Not for further distribution.

Mainland China—This material is provided to qualified investors only. No invitation to offer, or offer for, or sale of, the shares will be made in the mainland of the People's Republic of China ("Mainland China", not including the Hong Kong or Macau Special Administrative Regions or Taiwan) or by any means that would be deemed public under the laws of the Mainland China. The information relating to the strategy contained in this material has not been submitted to or approved by the China Securities Regulatory Commission or any other relevant governmental authority in the Mainland China. The strategy and/or any product associated with the strategy may only be offered or sold to investors in the Mainland China that are expressly authorized under the laws and regulations of the Mainland China to buy and sell securities denominated in a currency other than the Renminbi (or RMB), which is the official currency of the Mainland China. Potential investors who are resident in the Mainland China are responsible for obtaining the required approvals from all relevant government authorities in the Mainland China, including, but not limited to, the State Administration of Foreign Exchange, before purchasing the shares. This document further does not constitute any securities or investment advice to citizens of the Mainland China, or nationals with permanent residence in the Mainland China, or to any corporation, partnership, or other entity incorporated or established in the Mainland China.

Malaysia—This material can only be delivered to specific institutional investor. This material is solely for institutional use and for informational purposes only. This material does not provide investment advice or an offering to make, or an inducement or attempted inducement of any person to enter into or to offer to enter into, an agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. Nothing in this material shall be considered a making available of, solicitation to buy, an offering for subscription or purchase or an invitation to subscribe for or purchase any securities, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of Malaysia.

New Zealand—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

Philippines—ANY STRATEGY AND/ OR ANY SECURITIES ASSOCIATED WITH THE STRATEGY BEING DISCUSSED HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE. ANY FUTURE OFFER OR SALE OF THE STRATEGY AND/ OR ANY SECURITIES IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE, UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.

Singapore—Issued by T. Rowe Price Singapore Private Ltd. (UEN: 201021137E), 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. For Institutional and Accredited Investors only.

South Africa—Issued in South Africa by T. Rowe Price International Ltd (TRPIL), Warwick Court, 5 Paternoster Square, London EC4M 7DX, is an authorised financial services provider under the Financial Advisory and Intermediary Services Act, 2002 (Financial Services Provider (FSP) Licence Number 31935), authorised to provide "intermediary services" to South African Investors. TRPIL's Complaint Handling Procedures are available to clients upon request. The Financial Advisory and Intermediary Services Act Ombud in South Africa deals with complaints from clients against FSPs in relation to the specific services rendered by FSPs. The contact details are noted below: Telephone: +27 12 762 5000, Web: www.faisombud.co.za, Email: info@faisombud.co.za

Switzerland—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

Taiwan—This does not provide investment advice or recommendations. Nothing in this material shall be considered a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person in the Republic of China.

Thailand—This material has not been and will not be filed with or approved by the Securities Exchange Commission of Thailand or any other regulatory authority in Thailand. The material is provided solely to "institutional investors" as defined under relevant Thai laws and regulations. No distribution of this material to any member of the public in Thailand is permitted. Nothing in this material shall be considered a provision of service, or a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person where such provision, offer, solicitation, purchase or sale would be unlawful under relevant Thai laws and regulations.

UK—This material is issued and approved by T. Rowe Price International Ltd, Warwick Court, 5 Paternoster Square, London EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

USA—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which is regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

© 2024 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.